Previous Close | 1.7000 |
Open | 1.6900 |
Bid | 1.8000 |
Ask | 2.2000 |
Strike | 35.00 |
Expire Date | 2025-01-17 |
Day's Range | 1.6900 - 1.7000 |
Contract Range | N/A |
Volume | |
Open Interest | 32 |
Investors in Axsome Therapeutics, Inc. ( NASDAQ:AXSM ) had a good week, as its shares rose 2.0% to close at US$75.68...
NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in two upcoming investor conferences. The presentation details are as follows: RBC Capital Markets 2024 Global Healthcare Conference, on Tuesday, May 14, at 1:35 p.m. Eastern Time. Dr. Tabu
Axsome's (AXSM) bottom line declines year over year in the first quarter. Strong sales of Auvelity drive revenues.